Targeted therapies using BTK inhibitors (BTKi) and/or BCL2 inhibitors (BCL2i) represent a paradigm shift in the management of patients with chronic lymphocytic leukemia (CLL) and have led to significant improvements in patient outcomes. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.